WallStSmart

Live Ventures Inc (LIVE)vsMEDIFAST INC (MED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Live Ventures Inc generates 27% more annual revenue ($437.87M vs $346.10M). LIVE leads profitability with a 0.9% profit margin vs -5.8%. MED earns a higher WallStSmart Score of 45/100 (D).

LIVE

Avoid

33

out of 100

Grade: F

Growth: 4.0Profit: 4.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 2.02

MED

Hold

45

out of 100

Grade: D

Growth: 2.0Profit: 2.0Value: 6.0Quality: 8.5
Piotroski: 2/9Altman Z: 4.98
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LIVEUndervalued (+86.4%)

Margin of Safety

+86.4%

Fair Value

$143.82

Current Price

$9.06

$134.76 discount

UndervaluedFair: $143.82Overvalued

Intrinsic value data unavailable for MED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LIVE1 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

MED4 strengths · Avg: 9.5/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.9810/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.978/10

Growing faster than its price suggests

Areas to Watch

LIVE4 concerns · Avg: 3.0/10
Market CapQuality
$28.66M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.2%3/10

ROE of 4.2% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

MED4 concerns · Avg: 2.5/10
Market CapQuality
$134.54M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-10.1%2/10

ROE of -10.1% — below average capital efficiency

Revenue GrowthGrowth
-34.3%2/10

Revenue declined 34.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : LIVE

The strongest argument for LIVE centers on Price/Book.

Bull Case : MED

The strongest argument for MED centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bear Case : LIVE

The primary concerns for LIVE are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 2.50 is elevated, increasing financial risk. Thin 0.9% margins leave little buffer for downturns.

Bear Case : MED

The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

LIVE profiles as a value stock while MED is a turnaround play — different risk/reward profiles.

LIVE carries more volatility with a beta of 0.99 — expect wider price swings.

LIVE is growing revenue faster at -3.8% — sustainability is the question.

MED generates stronger free cash flow (-836,000), providing more financial flexibility.

Bottom Line

MED scores higher overall (45/100 vs 33/100). LIVE offers better value entry with a 86.4% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Live Ventures Inc

CONSUMER CYCLICAL · HOME IMPROVEMENT RETAIL · USA

Live Ventures Incorporated is engaged in flooring manufacturing, steel fabrication and retail businesses in the United States. The company is headquartered in Las Vegas, Nevada.

Visit Website →

MEDIFAST INC

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.

Visit Website →

Want to dig deeper into these stocks?